[go: up one dir, main page]

MA31285B1 - Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci - Google Patents

Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci

Info

Publication number
MA31285B1
MA31285B1 MA32239A MA32239A MA31285B1 MA 31285 B1 MA31285 B1 MA 31285B1 MA 32239 A MA32239 A MA 32239A MA 32239 A MA32239 A MA 32239A MA 31285 B1 MA31285 B1 MA 31285B1
Authority
MA
Morocco
Prior art keywords
dihydro
substituted
trihydroxazoloperimidine
exchanger
preparation
Prior art date
Application number
MA32239A
Other languages
Arabic (ar)
English (en)
Inventor
Bin Cao
Vieroslava Gurunian
Sathapana Kongsamut
Jr Raymond W Kosley
Rosy Sher
Ryan E Hartung
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31285B1 publication Critical patent/MA31285B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne une série de dihydro et tétrahydro oxazolopyrimidinones substituées, spécifiquement, une série de 2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones 2-substituées et de 2,3,5,6-tétra-hydro-oxazolo[3,2-a]pyrimidin-7-ones 2-substituées de formule (i) : dans laquelle p, n, x, y, r1, r2, r3, r4, r5, r6, r7 et r8 sont tels que définis dans le présent document. L'invention concerne également des procédés de fabrication de ces composés y compris de nouveaux intermédiaires. Les composés de cette invention sont des modulateurs des récepteurs métabotropiques du glutamate (mglur), particulièrement, du récepteur mglur2.
MA32239A 2007-03-09 2009-10-01 Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci MA31285B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89399107P 2007-03-09 2007-03-09
PCT/US2008/056002 WO2008112483A2 (fr) 2007-03-09 2008-03-06 Dihydro et tétrahydro oxazolopyrimidinones substituées, préparation et utilisation de celles-ci

Publications (1)

Publication Number Publication Date
MA31285B1 true MA31285B1 (fr) 2010-04-01

Family

ID=39760318

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32239A MA31285B1 (fr) 2007-03-09 2009-10-01 Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci

Country Status (23)

Country Link
US (1) US8642603B2 (fr)
EP (1) EP2137193B1 (fr)
JP (1) JP5351056B2 (fr)
KR (1) KR101547573B1 (fr)
CN (2) CN104447792A (fr)
AR (1) AR065651A1 (fr)
AU (1) AU2008226649B2 (fr)
BR (1) BRPI0808678A2 (fr)
CA (1) CA2680262C (fr)
CL (1) CL2008000691A1 (fr)
CO (1) CO6231034A2 (fr)
IL (1) IL200695A (fr)
MA (1) MA31285B1 (fr)
MX (1) MX2009009447A (fr)
MY (1) MY147757A (fr)
NZ (1) NZ579431A (fr)
PE (1) PE20090158A1 (fr)
RU (1) RU2470937C2 (fr)
SG (2) SG179453A1 (fr)
TW (1) TWI417296B (fr)
UY (1) UY30954A1 (fr)
WO (1) WO2008112483A2 (fr)
ZA (1) ZA200905564B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN104447792A (zh) 2007-03-09 2015-03-25 赛诺菲-安万特股份有限公司 取代的二氢和四氢噁唑并嘧啶酮及其制备和用途
EP2200985B1 (fr) 2007-09-14 2011-07-13 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 4-(aryl-x-phényl)-1h-pyridine-2-ones 1,3-disubstituées
CA2696948C (fr) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1, 4'] bipyridinyl-2'-ones 1', 3'-disusbstituees
NZ584148A (en) 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
US8207181B2 (en) 2008-03-06 2012-06-26 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
WO2009110901A1 (fr) * 2008-03-06 2009-09-11 Sanofi-Aventis Dihydro-, trihydro- et tétrahydro- cycloalkyloxazolopyrimidinones substituées, préparation et utilisation de celles-ci en tant que modulateurs allostériques de mglur
CN102143955B (zh) 2008-09-02 2013-08-14 Omj制药公司 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
WO2010043396A1 (fr) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Dérivés d’indole et de benzomorpholine en tant que modulateurs des récepteurs métabotropiques du glutamate
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
CA2769263C (fr) 2009-07-31 2017-03-07 Global Alliance For Tb Drug Development Analogues de nitro-imidazo-oxazine et de nitro-imidazo-oxazole et leurs utilisations
AR078173A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso
AR078172A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur
AR078171A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas
EP2563143A4 (fr) * 2010-04-29 2013-09-25 Merck Sharp & Dohme 1,3-benzothiazol-2(3h)-ones et [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones substituées formant des effecteurs allostériques positifs de mglur2
EP2611298A4 (fr) * 2010-08-31 2014-07-30 Univ Vanderbilt Composés bicycliques d'oxazole et de thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs mglur5
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CA2814998C (fr) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. Derives de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
JP2013544891A (ja) 2010-12-08 2013-12-19 ヴァンダービルト ユニバーシティー ｍＧＬＵＲ５受容体のアロステリック調節剤としての二環式ピラゾール化合物
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
EA033889B1 (ru) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR20200032702A (ko) * 2017-07-27 2020-03-26 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도
EP3604320A1 (fr) 2018-08-01 2020-02-05 Covestro Deutschland AG Poly(oxyalkylène)polyols ayant des groupes du phosphore fonctionnels et leur procédé de fabrication
CN112794860B (zh) * 2021-03-24 2021-06-29 上海肇钰医药科技有限公司 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途
CN115477607B (zh) * 2022-10-14 2024-05-24 肖尖 一种光稳定剂中间体及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH517688A (de) * 1969-07-09 1972-01-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy-essigsäurederivaten
FR2724171B1 (fr) * 1994-09-05 1997-01-03 Synthelabo Derives de 3,3a,4,5-tetrahydro-1h-oxazolo(3,4-a)quinolein-1-one, leur preparation et leur application en therapeutique
SI1368358T1 (sl) 2001-02-21 2007-02-28 Janssen Pharmaceutica Nv Izoksazolinski derivati kot antidepresivi
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101087771A (zh) 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
US7786888B2 (en) * 2006-10-30 2010-08-31 Honeywell International Inc. False ceiling fire detector assembly
CN104447792A (zh) 2007-03-09 2015-03-25 赛诺菲-安万特股份有限公司 取代的二氢和四氢噁唑并嘧啶酮及其制备和用途
AR078171A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas

Also Published As

Publication number Publication date
MX2009009447A (es) 2009-09-14
MY147757A (en) 2013-01-15
CA2680262A1 (fr) 2008-09-18
TWI417296B (zh) 2013-12-01
AU2008226649B2 (en) 2013-08-01
BRPI0808678A2 (pt) 2014-08-12
ZA200905564B (en) 2010-05-26
UY30954A1 (es) 2008-10-31
EP2137193B1 (fr) 2017-08-09
US20100075994A1 (en) 2010-03-25
JP5351056B2 (ja) 2013-11-27
KR101547573B1 (ko) 2015-08-26
IL200695A0 (en) 2010-05-17
JP2010520880A (ja) 2010-06-17
RU2009137369A (ru) 2011-04-20
NZ579431A (en) 2012-04-27
CL2008000691A1 (es) 2008-09-12
CN101675060A (zh) 2010-03-17
CA2680262C (fr) 2012-11-13
CN104447792A (zh) 2015-03-25
KR20090121381A (ko) 2009-11-25
CO6231034A2 (es) 2010-12-20
AR065651A1 (es) 2009-06-24
AU2008226649A1 (en) 2008-09-18
WO2008112483A2 (fr) 2008-09-18
IL200695A (en) 2014-11-30
RU2470937C2 (ru) 2012-12-27
EP2137193A2 (fr) 2009-12-30
TW200900409A (en) 2009-01-01
SG179453A1 (en) 2012-04-27
WO2008112483A3 (fr) 2009-01-15
SG10201506994RA (en) 2015-10-29
PE20090158A1 (es) 2009-04-23
US8642603B2 (en) 2014-02-04

Similar Documents

Publication Publication Date Title
MA31285B1 (fr) Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA34078B1 (fr) Derives d'arylethynyle
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
MA32882B1 (fr) Nouveaux pyrazole-4-n-alkoxycarboxamides en tant que microbiocides
EA201190302A1 (ru) ПРОИЗВОДНЫЕ 7-АРИЛ-1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA31703B1 (fr) Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
MA32391B1 (fr) Activateurs de la glucokinase
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
EA200870196A1 (ru) Индолсульфонамидные модуляторы рецепторов прогестерона
MA31597B1 (fr) Nouveaux herbicides
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
ATE384039T1 (de) Indanderivate als muscarinrezeptoragonisten
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA32537B1 (fr) Dérivés de pyrazolo [5,1-b] oxazole en tant qu'antagonistes de crf1
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
MA32173B1 (fr) Derives de pyridin-2-yle utilises comme agents immunomodulateurs